NO313186B1 - Dimer-selektive RXR modulatorer, farmasöytisk preparat omfattende samme og anvendelse derav for fremstilling avmedikament - Google Patents
Dimer-selektive RXR modulatorer, farmasöytisk preparat omfattende samme og anvendelse derav for fremstilling avmedikament Download PDFInfo
- Publication number
- NO313186B1 NO313186B1 NO19981501A NO981501A NO313186B1 NO 313186 B1 NO313186 B1 NO 313186B1 NO 19981501 A NO19981501 A NO 19981501A NO 981501 A NO981501 A NO 981501A NO 313186 B1 NO313186 B1 NO 313186B1
- Authority
- NO
- Norway
- Prior art keywords
- tetramethyl
- compound
- tetrahydro
- acid
- benzoic acid
- Prior art date
Links
- 239000000539 dimer Substances 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 347
- 238000000034 method Methods 0.000 claims abstract description 42
- 102000027507 nuclear receptors type II Human genes 0.000 claims abstract description 17
- 108091008686 nuclear receptors type II Proteins 0.000 claims abstract description 17
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 232
- 239000000203 mixture Substances 0.000 claims description 124
- 239000002253 acid Substances 0.000 claims description 95
- -1 4-[(propoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbonyl]benzoic acid oxime Chemical compound 0.000 claims description 91
- 239000005711 Benzoic acid Substances 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 34
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 33
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 33
- 235000010233 benzoic acid Nutrition 0.000 claims description 28
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 14
- 150000002923 oximes Chemical class 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- BCNMQHQVRAKRMK-UHFFFAOYSA-N 4-(3-butoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound CCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 BCNMQHQVRAKRMK-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- HQSQRAQVCDXZBN-UHFFFAOYSA-N 4-(3-butoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)-n-methoxybenzamide Chemical compound CCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NOC)C=C1 HQSQRAQVCDXZBN-UHFFFAOYSA-N 0.000 claims description 7
- WRCPCAXZNGRPPP-UHFFFAOYSA-N 4-(3-ethoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)-n-methoxybenzamide Chemical compound CCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NOC)C=C1 WRCPCAXZNGRPPP-UHFFFAOYSA-N 0.000 claims description 7
- GKVDKAQCDKZNQQ-UHFFFAOYSA-N 4-(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydroanthracene-1-carbonyl)benzoic acid Chemical compound C1=C(O)C=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=C1C(=O)C1=CC=C(C(O)=O)C=C1 GKVDKAQCDKZNQQ-UHFFFAOYSA-N 0.000 claims description 7
- YXXWSDZHLPQRNO-UHFFFAOYSA-N 4-[(6,6,9,9-tetramethyl-2,3,7,8-tetrahydrobenzo[g][1,4]benzoxazin-4-yl)methyl]benzoic acid Chemical compound C1COC=2C=C3C(C)(C)CCC(C)(C)C3=CC=2N1CC1=CC=C(C(O)=O)C=C1 YXXWSDZHLPQRNO-UHFFFAOYSA-N 0.000 claims description 7
- LXXRIBXGPHTXMM-UHFFFAOYSA-N 4-[(6,6,9,9-tetramethyl-3,4,7,8-tetrahydro-2h-benzo[g]quinolin-1-yl)methyl]benzoic acid Chemical compound C1CCC=2C=C3C(C)(C)CCC(C)(C)C3=CC=2N1CC1=CC=C(C(O)=O)C=C1 LXXRIBXGPHTXMM-UHFFFAOYSA-N 0.000 claims description 7
- NDBBQNFYMIIZSD-HAPMQHLFSA-N CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CC1C\C=C\C(\C)=C\C(O)=O Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CC1C\C=C\C(\C)=C\C(O)=O NDBBQNFYMIIZSD-HAPMQHLFSA-N 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- PICMLIQJGLIAFR-UHFFFAOYSA-N n-hexoxy-4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)benzamide Chemical compound C1=CC(C(O)=NOCCCCCC)=CC=C1C(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C PICMLIQJGLIAFR-UHFFFAOYSA-N 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- HPYZJJSRCVAZLZ-NXOKQZBISA-N (2e,4e)-3-methyl-5-[2-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopentyl]penta-2,4-dienoic acid Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CCCC1\C=C\C(\C)=C\C(O)=O HPYZJJSRCVAZLZ-NXOKQZBISA-N 0.000 claims description 6
- YOYWDYIPQNDPMQ-UHFFFAOYSA-N 4-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 YOYWDYIPQNDPMQ-UHFFFAOYSA-N 0.000 claims description 6
- JRMIMTUVDBKRAP-UHFFFAOYSA-N 4-[2-(3-ethoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid Chemical compound CCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C=CC1=CC=C(C(O)=O)C=C1 JRMIMTUVDBKRAP-UHFFFAOYSA-N 0.000 claims description 6
- QRVRZDDMQHFHMF-UHFFFAOYSA-N 4-[3-[(4-bromophenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl]-n-hydroxybenzamide Chemical compound C=1C=C(Br)C=CC=1COC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)C1=CC=C(C(O)=NO)C=C1 QRVRZDDMQHFHMF-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- WCOQMLFOGFSJFK-DADZOFOBSA-N (2E,4E,6E)-3-methyl-7-[2-phenylmethoxy-3,5-di(propan-2-yl)phenyl]octa-2,4,6-trienoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(\C)C1=CC(C(C)C)=CC(C(C)C)=C1OCC1=CC=CC=C1 WCOQMLFOGFSJFK-DADZOFOBSA-N 0.000 claims description 5
- ASGJIFSCRFREGM-JPWGDCLXSA-N (2e,4e)-3-methyl-7-[1-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hepta-2,4-dienoic acid Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CC\C=C\C(\C)=C\C(O)=O)CC1 ASGJIFSCRFREGM-JPWGDCLXSA-N 0.000 claims description 5
- VAHYHAIEBMCUDU-CZTLAYJYSA-N (2e,4e,6e)-7-[2-butoxy-3,5-di(propan-2-yl)phenyl]-3-methylocta-2,4,6-trienoic acid Chemical compound CCCCOC1=C(C(C)C)C=C(C(C)C)C=C1\C(C)=C\C=C\C(\C)=C\C(O)=O VAHYHAIEBMCUDU-CZTLAYJYSA-N 0.000 claims description 5
- GJJKXSNVYUOUFH-UHFFFAOYSA-N 4-(3-hexoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)-n-hydroxybenzamide Chemical compound CCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NO)C=C1 GJJKXSNVYUOUFH-UHFFFAOYSA-N 0.000 claims description 5
- STENGAKFDPGWAJ-UHFFFAOYSA-N 4-[(5,5,8,8-tetramethyl-6,7-dihydroanthracen-1-yl)methyl]benzoic acid Chemical compound C1=CC=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=C1CC1=CC=C(C(O)=O)C=C1 STENGAKFDPGWAJ-UHFFFAOYSA-N 0.000 claims description 5
- ACFZDZUXIGZKQL-UHFFFAOYSA-N 4-[1-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]benzoic acid Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=2C=CC(=CC=2)C(O)=O)CC1 ACFZDZUXIGZKQL-UHFFFAOYSA-N 0.000 claims description 5
- NFPJWVOWPUMOFB-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C=CC1=CC=C(C(O)=O)C=C1 NFPJWVOWPUMOFB-UHFFFAOYSA-N 0.000 claims description 5
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- BYMCAGYGWHXXLZ-UHFFFAOYSA-N n-hydroxy-4-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalene-2-carbonyl)benzamide Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NO)C=C1 BYMCAGYGWHXXLZ-UHFFFAOYSA-N 0.000 claims description 5
- XFKKCDSEDHHVTL-UHFFFAOYSA-N n-methoxy-4-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalene-2-carbonyl)benzamide Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NOC)C=C1 XFKKCDSEDHHVTL-UHFFFAOYSA-N 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- JNIDNWNTAWLGRV-HHCIPSQLSA-N (2e,4e)-7-[1-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]-3-methylhepta-2,4-dienoic acid Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CC\C=C\C(\C)=C\C(O)=O)CC1 JNIDNWNTAWLGRV-HHCIPSQLSA-N 0.000 claims description 4
- WHRNUWSQEGEWHX-ZEEVWJLDSA-N (2e,4e,6z)-7-[2-heptoxy-3,5-di(propan-2-yl)phenyl]-3-methylocta-2,4,6-trienoic acid Chemical compound CCCCCCCOC1=C(C(C)C)C=C(C(C)C)C=C1\C(C)=C/C=C/C(/C)=C/C(O)=O WHRNUWSQEGEWHX-ZEEVWJLDSA-N 0.000 claims description 4
- XDPRSZKAOSRGIF-UHFFFAOYSA-N 4-[2-(3-butoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid Chemical compound CCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C=CC1=CC=C(C(O)=O)C=C1 XDPRSZKAOSRGIF-UHFFFAOYSA-N 0.000 claims description 4
- OZMDVUWOODUUOQ-UHFFFAOYSA-N 4-[hydroxy-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-1-yl)methyl]benzoic acid Chemical compound C1=CC=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=C1C(O)C1=CC=C(C(O)=O)C=C1 OZMDVUWOODUUOQ-UHFFFAOYSA-N 0.000 claims description 4
- 229930194542 Keto Natural products 0.000 claims description 4
- 125000000468 ketone group Chemical group 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 claims description 3
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 claims description 3
- CCPAFZDTLKYSFR-UHFFFAOYSA-N 4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)-n-phenylmethoxybenzamide Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C(C=C1)=CC=C1C(O)=NOCC1=CC=CC=C1 CCPAFZDTLKYSFR-UHFFFAOYSA-N 0.000 claims description 3
- YOWZABQYDVPNGG-UHFFFAOYSA-N 4-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)-n-hydroxybenzamide Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NO)C=C1 YOWZABQYDVPNGG-UHFFFAOYSA-N 0.000 claims description 3
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 claims description 3
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 claims description 3
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 claims description 3
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 claims description 3
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 claims description 3
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 claims description 3
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- QIPXHRQAYOQRDT-UHFFFAOYSA-N 3-methylocta-2,4,6-trienoic acid Chemical compound CC=CC=CC(C)=CC(O)=O QIPXHRQAYOQRDT-UHFFFAOYSA-N 0.000 claims description 2
- NJVZEYZGZXBXBL-UHFFFAOYSA-N 4-[(5,5,8,8-tetramethyl-3,4,6,7-tetrahydroanthracen-1-yl)methyl]benzoic acid Chemical compound C=1CCC=2C=C3C(C)(C)CCC(C)(C)C3=CC=2C=1CC1=CC=C(C(O)=O)C=C1 NJVZEYZGZXBXBL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000001817 pituitary effect Effects 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 3
- 230000003779 hair growth Effects 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000003659 hair regrowth Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 59
- 239000000556 agonist Substances 0.000 abstract description 45
- 239000005557 antagonist Substances 0.000 abstract description 39
- 239000000710 homodimer Substances 0.000 abstract description 17
- 239000004031 partial agonist Substances 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 284
- 239000000243 solution Substances 0.000 description 240
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 236
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 224
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 184
- 108010038912 Retinoid X Receptors Proteins 0.000 description 171
- 102000034527 Retinoid X Receptors Human genes 0.000 description 171
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 136
- 238000005481 NMR spectroscopy Methods 0.000 description 111
- 235000019439 ethyl acetate Nutrition 0.000 description 109
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- 239000007787 solid Substances 0.000 description 88
- 125000003118 aryl group Chemical class 0.000 description 85
- 238000005160 1H NMR spectroscopy Methods 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 77
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 75
- 239000003921 oil Substances 0.000 description 74
- 235000019198 oils Nutrition 0.000 description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 69
- 150000002148 esters Chemical class 0.000 description 60
- 102000003702 retinoic acid receptors Human genes 0.000 description 60
- 108090000064 retinoic acid receptors Proteins 0.000 description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- 238000010626 work up procedure Methods 0.000 description 56
- 239000012267 brine Substances 0.000 description 49
- 239000000047 product Substances 0.000 description 49
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 49
- 150000001299 aldehydes Chemical class 0.000 description 48
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 45
- 230000007062 hydrolysis Effects 0.000 description 45
- 238000006460 hydrolysis reaction Methods 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 239000011734 sodium Substances 0.000 description 39
- 239000000833 heterodimer Substances 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 36
- 239000002904 solvent Substances 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 33
- 229920006395 saturated elastomer Polymers 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 238000004809 thin layer chromatography Methods 0.000 description 31
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 238000004587 chromatography analysis Methods 0.000 description 27
- 239000002585 base Substances 0.000 description 26
- 239000010410 layer Substances 0.000 description 26
- 238000000746 purification Methods 0.000 description 26
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 25
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 25
- 238000003556 assay Methods 0.000 description 25
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 25
- 108091008582 intracellular receptors Proteins 0.000 description 25
- 238000010992 reflux Methods 0.000 description 25
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 24
- 102000027411 intracellular receptors Human genes 0.000 description 24
- 239000003446 ligand Substances 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- 235000019502 Orange oil Nutrition 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 20
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 20
- 239000010502 orange oil Substances 0.000 description 20
- 150000007513 acids Chemical class 0.000 description 19
- 238000012761 co-transfection Methods 0.000 description 18
- OQKGPUSERILONW-UHFFFAOYSA-N ethyl 4-diethoxyphosphoryl-3-methylbut-2-enoate Chemical compound CCOC(=O)C=C(C)CP(=O)(OCC)OCC OQKGPUSERILONW-UHFFFAOYSA-N 0.000 description 18
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 17
- 230000027455 binding Effects 0.000 description 17
- 239000012230 colorless oil Substances 0.000 description 17
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 16
- 229930002330 retinoic acid Natural products 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 16
- 102000023984 PPAR alpha Human genes 0.000 description 15
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 15
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 14
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 229960002938 bexarotene Drugs 0.000 description 14
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 238000001953 recrystallisation Methods 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 229940121908 Retinoid X receptor agonist Drugs 0.000 description 13
- 125000004494 ethyl ester group Chemical group 0.000 description 13
- 238000006772 olefination reaction Methods 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 12
- 239000012467 final product Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 102100039556 Galectin-4 Human genes 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 150000002576 ketones Chemical class 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- 108010001515 Galectin 4 Proteins 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000012190 activator Substances 0.000 description 10
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 9
- 241001274216 Naso Species 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 108091008726 retinoic acid receptors α Proteins 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- JZVPKFOCLYDLDY-UHFFFAOYSA-N (4-ethoxy-2-methyl-4-oxobut-2-enyl)phosphonic acid Chemical compound CCOC(=O)C=C(C)CP(O)(O)=O JZVPKFOCLYDLDY-UHFFFAOYSA-N 0.000 description 8
- HSTAGCWQAIXJQM-UHFFFAOYSA-N 2,5-dichloro-2,5-dimethylhexane Chemical compound CC(C)(Cl)CCC(C)(C)Cl HSTAGCWQAIXJQM-UHFFFAOYSA-N 0.000 description 8
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 8
- 238000006130 Horner-Wadsworth-Emmons olefination reaction Methods 0.000 description 8
- 108091027981 Response element Proteins 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 229960001445 alitretinoin Drugs 0.000 description 8
- YOXHCYXIAVIFCZ-UHFFFAOYSA-N cyclopropanol Chemical compound OC1CC1 YOXHCYXIAVIFCZ-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 8
- 229910003002 lithium salt Inorganic materials 0.000 description 8
- 159000000002 lithium salts Chemical class 0.000 description 8
- 150000004492 retinoid derivatives Chemical class 0.000 description 8
- 102000027483 retinoid hormone receptors Human genes 0.000 description 8
- 108091008679 retinoid hormone receptors Proteins 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 229960001727 tretinoin Drugs 0.000 description 8
- IFHMELMOPNZNGD-UHFFFAOYSA-N 1-(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(O)C(C(=O)C)=C2 IFHMELMOPNZNGD-UHFFFAOYSA-N 0.000 description 7
- 101150041968 CDC13 gene Proteins 0.000 description 7
- 238000003547 Friedel-Crafts alkylation reaction Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 125000002348 vinylic group Chemical group 0.000 description 7
- 102000009310 vitamin D receptors Human genes 0.000 description 7
- 108050000156 vitamin D receptors Proteins 0.000 description 7
- SLXTWXQUEZSSTJ-UHFFFAOYSA-N 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=2N=CC(=CC=2)C(O)=O)CC1 SLXTWXQUEZSSTJ-UHFFFAOYSA-N 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101100202237 Danio rerio rxrab gene Proteins 0.000 description 6
- 101100309320 Danio rerio rxrga gene Proteins 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 101150050070 RXRA gene Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 150000001336 alkenes Chemical class 0.000 description 6
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 108020001756 ligand binding domains Proteins 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- LQKAVBZHAXSRCM-UHFFFAOYSA-N 4-(5,5,8,8-tetramethyl-6,7-dihydroanthracene-1-carbonyl)benzoic acid Chemical compound C1=CC=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=C1C(=O)C1=CC=C(C(O)=O)C=C1 LQKAVBZHAXSRCM-UHFFFAOYSA-N 0.000 description 5
- BKCSKXKHUPUMSQ-UHFFFAOYSA-N 4-[(5,5,8,8-tetramethyl-6,7-dihydro-1h-cyclopenta[b]naphthalen-3-yl)methyl]benzoic acid Chemical compound C=1CC=2C=C3C(C)(C)CCC(C)(C)C3=CC=2C=1CC1=CC=C(C(O)=O)C=C1 BKCSKXKHUPUMSQ-UHFFFAOYSA-N 0.000 description 5
- 238000010917 Friedel-Crafts cyclization Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 4
- ZTKZNANVHNGSEZ-UHFFFAOYSA-N 2-(5-ethyl-6-methyl-3-propan-2-ylheptoxy)-1-phenylethanone Chemical compound CCC(C(C)C)CC(C(C)C)CCOCC(=O)C1=CC=CC=C1 ZTKZNANVHNGSEZ-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- PHMRPWPDDRGGGF-UHFFFAOYSA-N 2-bromoprop-1-ene Chemical compound CC(Br)=C PHMRPWPDDRGGGF-UHFFFAOYSA-N 0.000 description 4
- SVPIJBNNVONPAR-UHFFFAOYSA-N 4-[(6,6,9,9-tetramethyl-2-oxo-3,4,7,8-tetrahydrobenzo[g]quinolin-1-yl)methyl]benzoic acid Chemical compound O=C1CCC=2C=C3C(C)(C)CCC(C)(C)C3=CC=2N1CC1=CC=C(C(O)=O)C=C1 SVPIJBNNVONPAR-UHFFFAOYSA-N 0.000 description 4
- SYZXLLBCMODKBA-UHFFFAOYSA-N 4-[1-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-1-yl)ethenyl]benzoic acid Chemical compound C1=CC=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=C1C(=C)C1=CC=C(C(O)=O)C=C1 SYZXLLBCMODKBA-UHFFFAOYSA-N 0.000 description 4
- LNKTWHHXQVLVID-UHFFFAOYSA-N 4-[1-hydroxy-1-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-1-yl)ethyl]benzoic acid Chemical compound C=1C=CC2=CC(C(CCC3(C)C)(C)C)=C3C=C2C=1C(O)(C)C1=CC=C(C(O)=O)C=C1 LNKTWHHXQVLVID-UHFFFAOYSA-N 0.000 description 4
- KSDHWFFJVXZZQP-UHFFFAOYSA-N 4-[2-methyl-1-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C=C(OCC=2C=CC=CC=2)C=1C(=C(C)C)C1=CC=C(C(O)=O)C=C1 KSDHWFFJVXZZQP-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 125000001743 benzylic group Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- PJGJQVRXEUVAFT-UHFFFAOYSA-N chloroiodomethane Chemical compound ClCI PJGJQVRXEUVAFT-UHFFFAOYSA-N 0.000 description 4
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 4
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 4
- 229950008441 clofibric acid Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 150000007857 hydrazones Chemical class 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- PZVOQKWDJGESRL-UHFFFAOYSA-N 1-bromo-3,4-dihydro-2h-naphthalen-1-ol Chemical compound C1=CC=C2C(O)(Br)CCCC2=C1 PZVOQKWDJGESRL-UHFFFAOYSA-N 0.000 description 3
- LSXKDWGTSHCFPP-UHFFFAOYSA-N 1-bromoheptane Chemical compound CCCCCCCBr LSXKDWGTSHCFPP-UHFFFAOYSA-N 0.000 description 3
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- RTKMFQOHBDVEBC-UHFFFAOYSA-N 3-bromo-3-buten-1-ol Chemical compound OCCC(Br)=C RTKMFQOHBDVEBC-UHFFFAOYSA-N 0.000 description 3
- PKIIGGDBIGMEOP-UHFFFAOYSA-N 4-[3-[(4-tert-butylphenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl]-n-hydroxybenzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1COC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NO)C=C1 PKIIGGDBIGMEOP-UHFFFAOYSA-N 0.000 description 3
- OPDGWSYNXPRREB-UHFFFAOYSA-N 5,6,7,8-tetramethyl-1,2,3,4-tetrahydronaphthalene Chemical class C1CCCC2=C(C)C(C)=C(C)C(C)=C21 OPDGWSYNXPRREB-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 3
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 3
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 3
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- SJNALLRHIVGIBI-UHFFFAOYSA-N alpha-vinylacetonitrile Natural products C=CCC#N SJNALLRHIVGIBI-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 238000010719 annulation reaction Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- VDEUYMSGMPQMIK-UHFFFAOYSA-N benzhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1 VDEUYMSGMPQMIK-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 3
- NKKMVIVFRUYPLQ-NSCUHMNNSA-N crotononitrile Chemical compound C\C=C\C#N NKKMVIVFRUYPLQ-NSCUHMNNSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000009699 differential effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 3
- 102000004311 liver X receptors Human genes 0.000 description 3
- 108090000865 liver X receptors Proteins 0.000 description 3
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 3
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- CDZKWOSJOWTGDN-UHFFFAOYSA-N n-hydroxy-4-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalene-2-carbonyl)benzamide Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NO)C=C1 CDZKWOSJOWTGDN-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 3
- 150000004714 phosphonium salts Chemical class 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000005556 structure-activity relationship Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- MFJWIXWFIVPWHB-UHFFFAOYSA-N 1,1,4,4-tetramethyl-6-prop-1-en-2-yl-7-propoxy-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=C)C(OCCC)=C2 MFJWIXWFIVPWHB-UHFFFAOYSA-N 0.000 description 2
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- WDXIVHZNWVSBQF-UHFFFAOYSA-N 2,4-dichloro-2,4-dimethylhexane Chemical compound CCC(C)(Cl)CC(C)(C)Cl WDXIVHZNWVSBQF-UHFFFAOYSA-N 0.000 description 2
- YBSFYIVMEAKTTH-UHFFFAOYSA-N 2-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-3-en-1-ol Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(CO)C=C)C(OCCCCCCC)=C2 YBSFYIVMEAKTTH-UHFFFAOYSA-N 0.000 description 2
- VZGKEVRUWFYIIJ-UHFFFAOYSA-N 3-(3-hexoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-2-enal Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC=O)C(OCCCCCC)=C2 VZGKEVRUWFYIIJ-UHFFFAOYSA-N 0.000 description 2
- RTXITYKPQXMDII-UHFFFAOYSA-N 3-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(OCCC)=C2 RTXITYKPQXMDII-UHFFFAOYSA-N 0.000 description 2
- VZCVUXXONUVWPE-UHFFFAOYSA-N 3-[2-heptoxy-3,5-di(propan-2-yl)phenyl]but-2-enal Chemical compound CCCCCCCOC1=C(C(C)C)C=C(C(C)C)C=C1C(C)=CC=O VZCVUXXONUVWPE-UHFFFAOYSA-N 0.000 description 2
- VQEXOOIXMOCCAE-UHFFFAOYSA-N 4-[2-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C=CC1=CC=C(C(O)=O)C=C1 VQEXOOIXMOCCAE-UHFFFAOYSA-N 0.000 description 2
- MSHVIFDMXOXHPN-UHFFFAOYSA-N 4-[3-[(4-tert-butylphenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl]benzoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1COC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 MSHVIFDMXOXHPN-UHFFFAOYSA-N 0.000 description 2
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
- UZHCJGSIRIFQTO-UHFFFAOYSA-N 5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-ol Chemical compound OC1=CC=C2C(C)(C)CCC(C)(C)C2=C1 UZHCJGSIRIFQTO-UHFFFAOYSA-N 0.000 description 2
- RFCVEUAESREIAI-UHFFFAOYSA-N 6,6,9,9-tetramethyl-1,2,3,4,7,8-hexahydrobenzo[g]quinoline Chemical compound N1CCCC2=C1C=C1C(C)(C)CCC(C)(C)C1=C2 RFCVEUAESREIAI-UHFFFAOYSA-N 0.000 description 2
- KWXMGYRIPFERMK-UHFFFAOYSA-N 6,6,9,9-tetramethyl-3,4,7,8-tetrahydro-2h-benzo[g][1,4]benzoxazine Chemical compound O1CCNC2=C1C=C1C(C)(C)CCC(C)(C)C1=C2 KWXMGYRIPFERMK-UHFFFAOYSA-N 0.000 description 2
- HTQZBSFWFJDOCN-UHFFFAOYSA-N 6-bromo-7-heptoxy-1,1,4,4-tetramethyl-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(Br)C(OCCCCCCC)=C2 HTQZBSFWFJDOCN-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 238000010934 O-alkylation reaction Methods 0.000 description 2
- TXQYHJPNWVRGHS-UHFFFAOYSA-N OB(O)OOCC1=CC=CC=C1 Chemical compound OB(O)OOCC1=CC=CC=C1 TXQYHJPNWVRGHS-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical class CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- RALDHUZFXJKFQB-UHFFFAOYSA-N cyclopentene-1-carbaldehyde Chemical compound O=CC1=CCCC1 RALDHUZFXJKFQB-UHFFFAOYSA-N 0.000 description 2
- 238000005888 cyclopropanation reaction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- IEARPTNIYZTWOZ-UHFFFAOYSA-N ethene Chemical compound [CH-]=C IEARPTNIYZTWOZ-UHFFFAOYSA-N 0.000 description 2
- OVSGLTPJNOAFBZ-PBFNJSJXSA-N ethyl (2E,4E,6E)-7-[2-heptoxy-3,5-di(propan-2-yl)phenyl]-3-methylocta-2,4,6-trienoate Chemical compound CCCCCCCOC1=C(C(C)C)C=C(C(C)C)C=C1\C(C)=C\C=C\C(\C)=C\C(=O)OCC OVSGLTPJNOAFBZ-PBFNJSJXSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MSBQKTPGPXCJIN-UHFFFAOYSA-N methyl 4-(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1O MSBQKTPGPXCJIN-UHFFFAOYSA-N 0.000 description 2
- YQOHARSOPCCWBR-UHFFFAOYSA-N methyl 4-[(6,6,9,9-tetramethyl-3,4,7,8-tetrahydro-2h-benzo[g]quinolin-1-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C2=CC(C(C)(C)CCC3(C)C)=C3C=C2CCC1 YQOHARSOPCCWBR-UHFFFAOYSA-N 0.000 description 2
- IUNRYBINYBKPAG-UHFFFAOYSA-N methyl 4-[2-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoate Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C=CC1=CC=C(C(=O)OC)C=C1 IUNRYBINYBKPAG-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LCPGWRMVTMQFOE-UHFFFAOYSA-N n-hydroxy-4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)benzamide Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=NO)C=C1 LCPGWRMVTMQFOE-UHFFFAOYSA-N 0.000 description 2
- NVFIKNIKBITITJ-UHFFFAOYSA-N n-phenylmethoxybenzamide Chemical compound C=1C=CC=CC=1C(=O)NOCC1=CC=CC=C1 NVFIKNIKBITITJ-UHFFFAOYSA-N 0.000 description 2
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- CWHFDTWZHFRTAB-UHFFFAOYSA-N phenyl cyanate Chemical compound N#COC1=CC=CC=C1 CWHFDTWZHFRTAB-UHFFFAOYSA-N 0.000 description 2
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 150000002266 vitamin A derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IPSRAFUHLHIWAR-UHFFFAOYSA-N zinc;ethane Chemical compound [Zn+2].[CH2-]C.[CH2-]C IPSRAFUHLHIWAR-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- NVGZJMUNKNRGHP-UHFFFAOYSA-N (1-bromo-2,2-dimethylpropyl)benzene Chemical compound CC(C)(C)C(Br)C1=CC=CC=C1 NVGZJMUNKNRGHP-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- HBWKYRPYWXHZQA-NXOKQZBISA-N (2e,4e)-3-methyl-5-[2-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopenten-1-yl]penta-2,4-dienoic acid Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=C(\C=C\C(\C)=C\C(O)=O)CCC1 HBWKYRPYWXHZQA-NXOKQZBISA-N 0.000 description 1
- QKYXJBDZCWIEPV-MHKYEALZSA-N (2e,4e)-3-methyl-6-[2-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hexa-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\CC1CC1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=CC=C1 QKYXJBDZCWIEPV-MHKYEALZSA-N 0.000 description 1
- PCADYIJEMCTLDY-PAERYZDYSA-N (2e,4e)-3-methyl-7-[1-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hepta-2,4-dienoic acid Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C=C(OCC=2C=CC=CC=2)C=1C1(CC/C=C/C(/C)=C/C(O)=O)CC1 PCADYIJEMCTLDY-PAERYZDYSA-N 0.000 description 1
- IAAPVNQZSBLWKH-ICDJNDDTSA-N (2e,4e,6e)-octa-2,4,6-trienoic acid Chemical compound C\C=C\C=C\C=C\C(O)=O IAAPVNQZSBLWKH-ICDJNDDTSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- JVHMVUFRZTZVNI-WOJGMQOQSA-N (E)-3-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)but-2-enal Chemical compound O=C\C=C(/C)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=CC=C1 JVHMVUFRZTZVNI-WOJGMQOQSA-N 0.000 description 1
- LVIGQRIQZSVKKV-UHFFFAOYSA-N 1,1,4,4-tetramethyl-6-phenylmethoxy-7-prop-1-en-2-yl-2,3-dihydronaphthalene Chemical compound CC(=C)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=CC=C1 LVIGQRIQZSVKKV-UHFFFAOYSA-N 0.000 description 1
- VTIBBOHXBURHMD-UHFFFAOYSA-N 1,2,3,4,4a,5,10,10a-octahydroanthracene Chemical class C1=CCC2CC(CCCC3)C3=CC2=C1 VTIBBOHXBURHMD-UHFFFAOYSA-N 0.000 description 1
- JAAJQSRLGAYGKZ-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C(O)CCCC2=C1 JAAJQSRLGAYGKZ-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PNWFXPGGROADNS-UHFFFAOYSA-N 1,2-dibromocyclopentene Chemical compound BrC1=C(Br)CCC1 PNWFXPGGROADNS-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- UOZJMNVKQLRYKF-UHFFFAOYSA-N 1-(3-butyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(CCCC)=C2 UOZJMNVKQLRYKF-UHFFFAOYSA-N 0.000 description 1
- IWMAPKWZERZITN-UHFFFAOYSA-N 1-(3-ethoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCC)=C2 IWMAPKWZERZITN-UHFFFAOYSA-N 0.000 description 1
- LTLJVLMUWFLRPL-UHFFFAOYSA-N 1-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropane-1-carbaldehyde Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=O)CC1 LTLJVLMUWFLRPL-UHFFFAOYSA-N 0.000 description 1
- RLJOJKNNESBAAA-UHFFFAOYSA-N 1-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCCCCCCC)=C2 RLJOJKNNESBAAA-UHFFFAOYSA-N 0.000 description 1
- JCEVJJXMELLEDK-UHFFFAOYSA-N 1-(3-hexoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCCCCCC)=C2 JCEVJJXMELLEDK-UHFFFAOYSA-N 0.000 description 1
- CJEAPVRPLWOYEN-UHFFFAOYSA-N 1-(3-methylbut-2-enoxy)naphthalene-2-carbonitrile Chemical compound C1=CC=C2C(OCC=C(C)C)=C(C#N)C=CC2=C1 CJEAPVRPLWOYEN-UHFFFAOYSA-N 0.000 description 1
- XUGYQPXRXVKPSD-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCCCCC)=C2 XUGYQPXRXVKPSD-UHFFFAOYSA-N 0.000 description 1
- FWUYHIAPPBCEJE-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)cyclopropane-1-carbaldehyde Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=CC(C2(CC2)C=O)=C1OCC1=CC=CC=C1 FWUYHIAPPBCEJE-UHFFFAOYSA-N 0.000 description 1
- BXIJKKOUHWQQOL-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=CC=C1 BXIJKKOUHWQQOL-UHFFFAOYSA-N 0.000 description 1
- IWEKYZSRKLANDJ-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopropane-1-carbaldehyde Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C=O)CC1 IWEKYZSRKLANDJ-UHFFFAOYSA-N 0.000 description 1
- GCOWIPWROXUSJD-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCCC)=C2 GCOWIPWROXUSJD-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- QZNQSIHCDAGZIA-UHFFFAOYSA-N 1-(bromomethyl)-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(CBr)C=C1 QZNQSIHCDAGZIA-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- DMHZDOTYAVHSEH-UHFFFAOYSA-N 1-(chloromethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCl)C=C1 DMHZDOTYAVHSEH-UHFFFAOYSA-N 0.000 description 1
- RHBSMFCUBPUVBF-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methoxy]naphthalene-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=C(C#N)C=CC2=CC=CC=C12 RHBSMFCUBPUVBF-UHFFFAOYSA-N 0.000 description 1
- IHGOYMBLWDUDHJ-UHFFFAOYSA-N 1-[(4-tert-butylphenyl)methoxy]naphthalene-2-carbonitrile Chemical compound C1=CC(C(C)(C)C)=CC=C1COC1=C(C#N)C=CC2=CC=CC=C12 IHGOYMBLWDUDHJ-UHFFFAOYSA-N 0.000 description 1
- YHXTZIBVJIOXBA-UHFFFAOYSA-N 1-[1-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]ethanol Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(C(C)O)CC1 YHXTZIBVJIOXBA-UHFFFAOYSA-N 0.000 description 1
- CJTBHDLSEFFTRQ-UHFFFAOYSA-N 1-[3-[(4-methoxyphenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl]ethanone Chemical compound C1=CC(OC)=CC=C1COC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(C)=O CJTBHDLSEFFTRQ-UHFFFAOYSA-N 0.000 description 1
- HMNJSMPOYZVOGO-UHFFFAOYSA-N 1-[3-[(4-tert-butylphenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl]ethanone Chemical compound CC(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=C(C(C)(C)C)C=C1 HMNJSMPOYZVOGO-UHFFFAOYSA-N 0.000 description 1
- FWZYMTHROFKVEX-UHFFFAOYSA-N 1-[5,5,8,8-tetramethyl-3-(2-methylpropoxy)-6,7-dihydronaphthalen-2-yl]ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCC(C)C)=C2 FWZYMTHROFKVEX-UHFFFAOYSA-N 0.000 description 1
- NYCIYZHQVCIKOP-UHFFFAOYSA-N 1-[5,5,8,8-tetramethyl-3-(3-methylbut-2-enoxy)-6,7-dihydronaphthalen-2-yl]ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(OCC=C(C)C)=C2 NYCIYZHQVCIKOP-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- GCKPJUYBKVPDAU-UHFFFAOYSA-N 1-butyl-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2C(CCCC)CCCC2=C1 GCKPJUYBKVPDAU-UHFFFAOYSA-N 0.000 description 1
- YUSHXVOWOKEAJU-UHFFFAOYSA-N 1-butylnaphthalene-2-carbonitrile Chemical compound C1=CC=C2C(CCCC)=C(C#N)C=CC2=C1 YUSHXVOWOKEAJU-UHFFFAOYSA-N 0.000 description 1
- UDMRXJVASPGFQM-UHFFFAOYSA-N 1-hexoxynaphthalene Chemical compound C1=CC=C2C(OCCCCCC)=CC=CC2=C1 UDMRXJVASPGFQM-UHFFFAOYSA-N 0.000 description 1
- CZRXBWSZZOJWJG-UHFFFAOYSA-N 1-hydroxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2C(O)C(=O)CCC2=C1 CZRXBWSZZOJWJG-UHFFFAOYSA-N 0.000 description 1
- QODMLJXRZPFPNI-UHFFFAOYSA-N 1-prop-1-enylcyclohexa-2,4-diene-1-carboxylic acid Chemical compound CC=CC1(C(O)=O)CC=CC=C1 QODMLJXRZPFPNI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N 2,4-Hexadienoic acid Chemical class CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- UTJNQCRRXGSSRT-UHFFFAOYSA-N 2-(3,5-ditert-butyl-2-heptoxyphenyl)butanenitrile Chemical compound CCCCCCCOC1=C(C(CC)C#N)C=C(C(C)(C)C)C=C1C(C)(C)C UTJNQCRRXGSSRT-UHFFFAOYSA-N 0.000 description 1
- UHMDTUMQYLPUCM-UHFFFAOYSA-N 2-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-2-en-1-ol Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(=C)CO)C(OCCCCCCC)=C2 UHMDTUMQYLPUCM-UHFFFAOYSA-N 0.000 description 1
- RPMCOQXFWHUZHH-UHFFFAOYSA-N 2-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)prop-2-en-1-ol Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=CC(C(=C)CO)=C1OCC1=CC=CC=C1 RPMCOQXFWHUZHH-UHFFFAOYSA-N 0.000 description 1
- DAOOJXUPJRFXEG-UHFFFAOYSA-N 2-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)but-3-en-1-ol Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(CO)C=C)C(OCCC)=C2 DAOOJXUPJRFXEG-UHFFFAOYSA-N 0.000 description 1
- JGHUZRREFKAMLY-UHFFFAOYSA-N 2-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)prop-1-en-1-ol Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CO)C(OCCC)=C2 JGHUZRREFKAMLY-UHFFFAOYSA-N 0.000 description 1
- UDEWQTUGDFZHCP-UHFFFAOYSA-N 2-[1-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]acetaldehyde Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CC=O)CC1 UDEWQTUGDFZHCP-UHFFFAOYSA-N 0.000 description 1
- BELMZQBDPANXEN-UHFFFAOYSA-N 2-[1-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]acetaldehyde Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=CC(C2(CC=O)CC2)=C1OCC1=CC=CC=C1 BELMZQBDPANXEN-UHFFFAOYSA-N 0.000 description 1
- GMSUZEPBYPZKRP-UHFFFAOYSA-N 2-[1-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]acetaldehyde Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CC=O)CC1 GMSUZEPBYPZKRP-UHFFFAOYSA-N 0.000 description 1
- UFLJQEQRKIIWBY-UHFFFAOYSA-N 2-[[3,5-di(propan-2-yl)phenyl]methoxy]-1-phenylethanone Chemical compound CC(C)C1=CC(C(C)C)=CC(COCC(=O)C=2C=CC=CC=2)=C1 UFLJQEQRKIIWBY-UHFFFAOYSA-N 0.000 description 1
- LOHOSHDZQVKDPS-UHFFFAOYSA-N 2-bromonaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Br)C=CC2=C1 LOHOSHDZQVKDPS-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- XUFUYOGWFZSHGE-UHFFFAOYSA-N 2-hydroxy-3,5-di(propan-2-yl)benzoic acid Chemical compound CC(C)C1=CC(C(C)C)=C(O)C(C(O)=O)=C1 XUFUYOGWFZSHGE-UHFFFAOYSA-N 0.000 description 1
- MRVNKBNZHOHVER-UHFFFAOYSA-N 2h-anthracen-1-one Chemical compound C1=CC=C2C=C3C(=O)CC=CC3=CC2=C1 MRVNKBNZHOHVER-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- QDZSNJMOMUKVRU-UHFFFAOYSA-N 3-(3,5-ditert-butyl-2-heptoxyphenyl)but-2-enenitrile Chemical compound CCCCCCCOC1=C(C(C)=CC#N)C=C(C(C)(C)C)C=C1C(C)(C)C QDZSNJMOMUKVRU-UHFFFAOYSA-N 0.000 description 1
- CGQZQYKLGMNEQO-UHFFFAOYSA-N 3-(3,5-ditert-butyl-2-heptoxyphenyl)butanenitrile Chemical compound CCCCCCCOC1=C(C(C)CC#N)C=C(C(C)(C)C)C=C1C(C)(C)C CGQZQYKLGMNEQO-UHFFFAOYSA-N 0.000 description 1
- HIGHCLBKIXTDFF-UHFFFAOYSA-N 3-(3-butyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-2-enal Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC=O)C(CCCC)=C2 HIGHCLBKIXTDFF-UHFFFAOYSA-N 0.000 description 1
- LASABYYIIFMOQA-UHFFFAOYSA-N 3-(3-butyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(CCCC)=C2 LASABYYIIFMOQA-UHFFFAOYSA-N 0.000 description 1
- LJVOQBMLERHFFA-UHFFFAOYSA-N 3-(3-ethoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-2-enal Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC=O)C(OCC)=C2 LJVOQBMLERHFFA-UHFFFAOYSA-N 0.000 description 1
- IFIFHVVCZURNBT-UHFFFAOYSA-N 3-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(OCCCCCCC)=C2 IFIFHVVCZURNBT-UHFFFAOYSA-N 0.000 description 1
- JYEOQMRYRXLCCH-UHFFFAOYSA-N 3-(3-hexoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(OCCCCCC)=C2 JYEOQMRYRXLCCH-UHFFFAOYSA-N 0.000 description 1
- XSUHBHFBJPSQEP-UHFFFAOYSA-N 3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)but-2-enal Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC=O)C(OCCCCC)=C2 XSUHBHFBJPSQEP-UHFFFAOYSA-N 0.000 description 1
- OQMKAGNRQILFGO-UHFFFAOYSA-N 3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(OCCCCC)=C2 OQMKAGNRQILFGO-UHFFFAOYSA-N 0.000 description 1
- HBOLBLJWUZIGLM-UHFFFAOYSA-N 3-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)butanal Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)CC=O)C(OCCC)=C2 HBOLBLJWUZIGLM-UHFFFAOYSA-N 0.000 description 1
- JIKXNWRTDZGSGD-UHFFFAOYSA-N 3-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)butanenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)CC#N)C(OCCC)=C2 JIKXNWRTDZGSGD-UHFFFAOYSA-N 0.000 description 1
- PIUJWZLADPWNTN-UHFFFAOYSA-N 3-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)prop-2-ynenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C#CC#N)C(OCCC)=C2 PIUJWZLADPWNTN-UHFFFAOYSA-N 0.000 description 1
- QGSIJZGXODOHMU-UHFFFAOYSA-N 3-[2-heptoxy-3,5-di(propan-2-yl)phenyl]but-2-enenitrile Chemical compound CCCCCCCOC1=C(C(C)C)C=C(C(C)C)C=C1C(C)=CC#N QGSIJZGXODOHMU-UHFFFAOYSA-N 0.000 description 1
- WWLQHLPUVWIBIO-UHFFFAOYSA-N 3-[3-[(4-tert-butylphenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl]but-2-enenitrile Chemical compound N#CC=C(C)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=C(C(C)(C)C)C=C1 WWLQHLPUVWIBIO-UHFFFAOYSA-N 0.000 description 1
- QSEILUMVSSGCEM-UHFFFAOYSA-N 3-[5,5,8,8-tetramethyl-3-(2-methylpropoxy)-6,7-dihydronaphthalen-2-yl]but-2-enal Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC=O)C(OCC(C)C)=C2 QSEILUMVSSGCEM-UHFFFAOYSA-N 0.000 description 1
- IQRLDRXLKJRSSQ-UHFFFAOYSA-N 3-[5,5,8,8-tetramethyl-3-(2-methylpropoxy)-6,7-dihydronaphthalen-2-yl]but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(OCC(C)C)=C2 IQRLDRXLKJRSSQ-UHFFFAOYSA-N 0.000 description 1
- UMPSCERWDZCTNU-UHFFFAOYSA-N 3-[5,5,8,8-tetramethyl-3-(3-methylbut-2-enoxy)-6,7-dihydronaphthalen-2-yl]but-2-enenitrile Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=CC#N)C(OCC=C(C)C)=C2 UMPSCERWDZCTNU-UHFFFAOYSA-N 0.000 description 1
- CBYVFFYWRXWFBH-UHFFFAOYSA-N 3-anthracen-1-yl-2-(hydroxymethyl)benzoic acid Chemical class OCC1=C(C(O)=O)C=CC=C1C1=CC=CC2=CC3=CC=CC=C3C=C12 CBYVFFYWRXWFBH-UHFFFAOYSA-N 0.000 description 1
- YWEGYQWOTPKCMT-UHFFFAOYSA-N 3-bromo-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-ol Chemical compound BrC1=C(O)C=C2C(C)(C)CCC(C)(C)C2=C1 YWEGYQWOTPKCMT-UHFFFAOYSA-N 0.000 description 1
- WGSISXQCCOFXKW-UHFFFAOYSA-N 3-bromobut-2-en-1-ol Chemical compound CC(Br)=CCO WGSISXQCCOFXKW-UHFFFAOYSA-N 0.000 description 1
- IAGXTPCOGVFRSQ-UHFFFAOYSA-N 4-(2-phenylethenyl)benzoic acid Chemical class C1=CC(C(=O)O)=CC=C1C=CC1=CC=CC=C1 IAGXTPCOGVFRSQ-UHFFFAOYSA-N 0.000 description 1
- QADGBOQVBUXZKO-UHFFFAOYSA-N 4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 QADGBOQVBUXZKO-UHFFFAOYSA-N 0.000 description 1
- PLRHPDHSKZBPIH-UHFFFAOYSA-N 4-(3-ethoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound CCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 PLRHPDHSKZBPIH-UHFFFAOYSA-N 0.000 description 1
- GGCJUSGFZYHGLN-UHFFFAOYSA-N 4-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 GGCJUSGFZYHGLN-UHFFFAOYSA-N 0.000 description 1
- GDILHIUGUNCNDU-UHFFFAOYSA-N 4-(4-oxochromen-2-yl)benzoic acid Chemical class C1=CC(C(=O)O)=CC=C1C1=CC(=O)C2=CC=CC=C2O1 GDILHIUGUNCNDU-UHFFFAOYSA-N 0.000 description 1
- IACHFHLVDGQJMY-UHFFFAOYSA-N 4-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound C=1C=CC=CC=1COC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)C1=CC=C(C(O)=O)C=C1 IACHFHLVDGQJMY-UHFFFAOYSA-N 0.000 description 1
- DMXMTUPNTQQZJO-UHFFFAOYSA-N 4-[2-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C=CC1=CC=C(C(O)=O)C=C1 DMXMTUPNTQQZJO-UHFFFAOYSA-N 0.000 description 1
- AIKVWLAJGOUAGW-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=CC(C2(OCCO2)C=2C=CC(=CC=2)C(O)=O)=C1OCC1=CC=CC=C1 AIKVWLAJGOUAGW-UHFFFAOYSA-N 0.000 description 1
- GCDFBDIFJURQKB-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalen-2-yl)ethyl]benzoic acid Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1CCC1=CC=C(C(O)=O)C=C1 GCDFBDIFJURQKB-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- REIDAMBAPLIATC-UHFFFAOYSA-M 4-methoxycarbonylbenzoate Chemical compound COC(=O)C1=CC=C(C([O-])=O)C=C1 REIDAMBAPLIATC-UHFFFAOYSA-M 0.000 description 1
- OCTKWQHDXPQFBP-UHFFFAOYSA-N 4-naphthalen-1-yloxybutanenitrile Chemical compound C1=CC=C2C(OCCCC#N)=CC=CC2=C1 OCTKWQHDXPQFBP-UHFFFAOYSA-N 0.000 description 1
- TUWBVBYVXBXGFD-UHFFFAOYSA-N 5,5,8,8-tetramethyl-3,4,6,7-tetrahydro-2h-anthracen-1-one Chemical compound O=C1CCCC2=C1C=C1C(C)(C)CCC(C)(C)C1=C2 TUWBVBYVXBXGFD-UHFFFAOYSA-N 0.000 description 1
- ITMGOZGTOYGNGI-UHFFFAOYSA-N 6,6,9,9-tetramethyl-3,4,7,8-tetrahydro-1h-benzo[g]quinolin-2-one Chemical compound N1C(=O)CCC2=C1C=C1C(C)(C)CCC(C)(C)C1=C2 ITMGOZGTOYGNGI-UHFFFAOYSA-N 0.000 description 1
- XKKPTZVGTLMOGN-UHFFFAOYSA-N 6,6,9,9-tetramethyl-7,8-dihydro-4h-benzo[g][1,4]benzoxazin-3-one Chemical compound O1CC(=O)NC2=C1C=C1C(C)(C)CCC(C)(C)C1=C2 XKKPTZVGTLMOGN-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- TWSRJDZTUMJNRV-UHFFFAOYSA-N 6-bromo-1,1,4,4-tetramethyl-7-propoxy-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(Br)C(OCCC)=C2 TWSRJDZTUMJNRV-UHFFFAOYSA-N 0.000 description 1
- WMCVWCDGMXHHSJ-UHFFFAOYSA-N 6-butyl-1,1,4,4-tetramethyl-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(CCCC)=CC=2 WMCVWCDGMXHHSJ-UHFFFAOYSA-N 0.000 description 1
- FKAQSGYSESPQEG-UHFFFAOYSA-N 6-heptoxy-1,1,4,4-tetramethyl-7-prop-1-en-2-yl-2,3-dihydronaphthalene Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=C)C(OCCCCCCC)=C2 FKAQSGYSESPQEG-UHFFFAOYSA-N 0.000 description 1
- OMDZIQQFRGDFAP-UHFFFAOYSA-N 6-hydroxycyclohexa-2,4-dien-1-one Chemical compound OC1C=CC=CC1=O OMDZIQQFRGDFAP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- BRQRGNJFUMJEDE-UHFFFAOYSA-N 8-naphthalen-1-yloxyoctanenitrile Chemical compound C1=CC=C2C(OCCCCCCCC#N)=CC=CC2=C1 BRQRGNJFUMJEDE-UHFFFAOYSA-N 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- RSZYFBMJWKFTNO-UHFFFAOYSA-N C(CC)OC1(CC=2C(CCC(C=2C=C1)(C)C)(C)C)C(=O)C1=CC=C(C(=O)O)C=C1 Chemical compound C(CC)OC1(CC=2C(CCC(C=2C=C1)(C)C)(C)C)C(=O)C1=CC=C(C(=O)O)C=C1 RSZYFBMJWKFTNO-UHFFFAOYSA-N 0.000 description 1
- SUTBMSAKRXAYPR-UHFFFAOYSA-N C(CC)OOB(O)O Chemical compound C(CC)OOB(O)O SUTBMSAKRXAYPR-UHFFFAOYSA-N 0.000 description 1
- BPGMAJFFCOQJDA-FVQVICRXSA-N CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CC1C(C)\C=C\C(\C)=C\C(O)=O Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CC1C(C)\C=C\C(\C)=C\C(O)=O BPGMAJFFCOQJDA-FVQVICRXSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100202242 Danio rerio rxrba gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 241000816584 Glauconycteris atra Species 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000603962 Homo sapiens Oxysterols receptor LXR-alpha Proteins 0.000 description 1
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 1
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021197 Ichthyoses Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150091136 Mob4 gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102100038476 Oxysterols receptor LXR-alpha Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 101150014691 PPARA gene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101710097927 Retinal-binding protein Proteins 0.000 description 1
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 1
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000006932 Simmons-Smith cyclopropanation reaction Methods 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DIVPXYVEDQFEMO-UHFFFAOYSA-N [1-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]methanol Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CO)CC1 DIVPXYVEDQFEMO-UHFFFAOYSA-N 0.000 description 1
- HVUVBIBITAXMHI-UHFFFAOYSA-N [1-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]methanol Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CO)CC1 HVUVBIBITAXMHI-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 150000004983 alkyl aryl ketones Chemical class 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000008841 allosteric interaction Effects 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 150000008430 aromatic amides Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- YWPVVTGIFVTDIN-UHFFFAOYSA-N bis[(4-methylphenyl)methyl] carbonate Chemical compound C1=CC(C)=CC=C1COC(=O)OCC1=CC=C(C)C=C1 YWPVVTGIFVTDIN-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentenylidene Natural products C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- VUPKGFBOKBGHFZ-UHFFFAOYSA-N dipropyl carbonate Chemical compound CCCOC(=O)OCCC VUPKGFBOKBGHFZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- NGECERUCAPRTGD-UHFFFAOYSA-N ethyl 3-methyl-6-[1-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hexa-2,4-dienoate Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C=C(OCC=2C=CC=CC=2)C=1C1(CC=CC(C)=CC(=O)OCC)CC1 NGECERUCAPRTGD-UHFFFAOYSA-N 0.000 description 1
- GZHIHDHMTSHCAG-UHFFFAOYSA-N ethyl 3-methyl-6-[1-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hexa-2,4-dienoate Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1(CC=CC(C)=CC(=O)OCC)CC1 GZHIHDHMTSHCAG-UHFFFAOYSA-N 0.000 description 1
- BGULJKKBULBXRU-UHFFFAOYSA-N ethyl 3-methyl-7-[2-(5,5,8,8-tetramethyl-3-phenylmethoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hepta-2,4-dienoate Chemical compound CCOC(=O)C=C(C)C=CCCC1CC1C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=CC=C1 BGULJKKBULBXRU-UHFFFAOYSA-N 0.000 description 1
- VNFLIZYKSVQXND-UHFFFAOYSA-N ethyl 3-methyl-7-[2-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)cyclopropyl]hepta-2,4-dienoate Chemical compound CCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CC1CCC=CC(C)=CC(=O)OCC VNFLIZYKSVQXND-UHFFFAOYSA-N 0.000 description 1
- JUQYGNSCOXWKTQ-UHFFFAOYSA-N ethyl 7-[2-(3-heptoxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]-3-methylhepta-2,4-dienoate Chemical compound CCCCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1CC1CCC=CC(C)=CC(=O)OCC JUQYGNSCOXWKTQ-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FUWYMLYVUVBWSU-UHFFFAOYSA-N heptoxyboronic acid Chemical compound CCCCCCCOB(O)O FUWYMLYVUVBWSU-UHFFFAOYSA-N 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QKASDIPENBEWBU-UHFFFAOYSA-N methyl 2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CBr QKASDIPENBEWBU-UHFFFAOYSA-N 0.000 description 1
- DYVLPJYIGJZAKF-UHFFFAOYSA-N methyl 4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C DYVLPJYIGJZAKF-UHFFFAOYSA-N 0.000 description 1
- DFLIYNPAVDVGGE-UHFFFAOYSA-N methyl 4-(5,5,8,8-tetramethyl-3,4,6,7-tetrahydroanthracene-1-carbonyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)C1=CCCC2=CC(C(CCC3(C)C)(C)C)=C3C=C12 DFLIYNPAVDVGGE-UHFFFAOYSA-N 0.000 description 1
- RVICEBUCDTWDCH-UHFFFAOYSA-N methyl 4-(5,5,8,8-tetramethyl-3-propyl-6,7-dihydronaphthalene-2-carbonyl)benzoate Chemical compound CCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(=O)OC)C=C1 RVICEBUCDTWDCH-UHFFFAOYSA-N 0.000 description 1
- FLTBQDFGTFBKHW-UHFFFAOYSA-N methyl 4-[(6,6,9,9-tetramethyl-2,3,7,8-tetrahydrobenzo[g][1,4]benzoxazin-4-yl)methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C2=CC(C(C)(C)CCC3(C)C)=C3C=C2OCC1 FLTBQDFGTFBKHW-UHFFFAOYSA-N 0.000 description 1
- HPMHXQNCWSAEHB-UHFFFAOYSA-N methyl 4-[3-[(4-bromophenyl)methoxy]-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1OCC1=CC=C(Br)C=C1 HPMHXQNCWSAEHB-UHFFFAOYSA-N 0.000 description 1
- KRNBQSIFSSHBTM-UHFFFAOYSA-N methyl 6-(oxomethylidene)cyclohexa-2,4-diene-1-carboxylate Chemical compound COC(=O)C1C=CC=CC1=C=O KRNBQSIFSSHBTM-UHFFFAOYSA-N 0.000 description 1
- WVWHCPXCEYRBBP-UHFFFAOYSA-N methyl n-hexoxy-4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)benzenecarboximidate Chemical compound C1=CC(C(OC)=NOCCCCCC)=CC=C1C(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1C WVWHCPXCEYRBBP-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- PBQZQTQFQFYBNJ-UHFFFAOYSA-N n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1 PBQZQTQFQFYBNJ-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical class [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006485 reductive methylation reaction Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940002683 retin-a Drugs 0.000 description 1
- 102000024458 retinal binding proteins Human genes 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220129615 rs767644139 Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CRLYHSUSQLYCCZ-UHFFFAOYSA-M sodium;azanide;methyl(triphenyl)phosphanium;bromide Chemical compound [NH2-].[Na+].[Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 CRLYHSUSQLYCCZ-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/33—Polycyclic acids
- C07C63/49—Polycyclic acids containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
- C07C65/36—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US489795P | 1995-10-06 | 1995-10-06 | |
US988496P | 1996-01-10 | 1996-01-10 | |
US1831896P | 1996-05-24 | 1996-05-24 | |
US2183996P | 1996-07-10 | 1996-07-10 | |
PCT/US1996/014876 WO1997012853A1 (en) | 1995-10-06 | 1996-09-17 | Dimer-selective rxr modulators and methods for their use |
Publications (3)
Publication Number | Publication Date |
---|---|
NO981501D0 NO981501D0 (no) | 1998-04-02 |
NO981501L NO981501L (no) | 1998-06-02 |
NO313186B1 true NO313186B1 (no) | 2002-08-26 |
Family
ID=27485410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19981501A NO313186B1 (no) | 1995-10-06 | 1998-04-02 | Dimer-selektive RXR modulatorer, farmasöytisk preparat omfattende samme og anvendelse derav for fremstilling avmedikament |
Country Status (14)
Country | Link |
---|---|
US (2) | US6545049B1 (es) |
EP (2) | EP0873295B1 (es) |
JP (1) | JP2002515025A (es) |
KR (1) | KR100625255B1 (es) |
AT (1) | ATE236115T1 (es) |
AU (1) | AU726450B2 (es) |
BR (1) | BR9610875A (es) |
CA (1) | CA2233888A1 (es) |
DE (1) | DE69627193T2 (es) |
DK (1) | DK0873295T3 (es) |
ES (1) | ES2190479T3 (es) |
NO (1) | NO313186B1 (es) |
PT (1) | PT873295E (es) |
WO (1) | WO1997012853A1 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7655699B1 (en) | 1992-04-22 | 2010-02-02 | Eisai Inc. | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
US7115728B1 (en) * | 1995-01-30 | 2006-10-03 | Ligand Pharmaceutical Incorporated | Human peroxisome proliferator activated receptor γ |
US6028052A (en) | 1995-09-18 | 2000-02-22 | Ligand Pharmaceuticals Incorporated | Treating NIDDM with RXR agonists |
AU725998B2 (en) * | 1995-09-18 | 2000-10-26 | Eisai R&D Management Co., Ltd. | Treating NIDDM with RXR agonists |
US6005007A (en) * | 1997-07-18 | 1999-12-21 | Farmer; Luc J. | Retinoids, methods for their production and use |
WO1999005161A1 (en) * | 1997-07-25 | 1999-02-04 | Ligand Pharmaceuticals Incorporated | HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR |
US5998654A (en) * | 1997-07-25 | 1999-12-07 | Ligand Pharmaceuticals Incorporated | Retinoic acid receptor antagonist compounds and methods |
ATE334673T1 (de) * | 1997-11-12 | 2006-08-15 | Hoffmann La Roche | Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten |
JP4204657B2 (ja) * | 1997-12-05 | 2009-01-07 | 有限会社ケムフィズ | 糖尿病の予防・治療剤 |
EP1077920A1 (en) * | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1077919A1 (en) * | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2003520758A (ja) * | 1998-06-12 | 2003-07-08 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 抗エストロゲン耐性乳癌のrxrモジュレーターを用いた処置 |
FR2780512B1 (fr) * | 1998-06-25 | 2003-10-17 | Lipha | Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique |
US6048873A (en) * | 1998-10-01 | 2000-04-11 | Allergan Sales, Inc. | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
US6403638B1 (en) | 1998-10-01 | 2002-06-11 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US6147224A (en) * | 1998-10-01 | 2000-11-14 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
WO2000026173A1 (en) * | 1998-11-03 | 2000-05-11 | Ligand Pharmaceuticals Incorporated | Novel retinoids, methods for their production and use |
JP4693247B2 (ja) | 1999-04-28 | 2011-06-01 | 有限会社ケムフィズ | 複素環カルボン酸誘導体 |
HUP0202814A3 (en) | 1999-08-27 | 2003-11-28 | Ligand Pharmaceuticals Inc San | Androgen receptor modulator compounds and methods for their preparation and pharmaceutical compositions containing them and their use |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
WO2001016133A2 (en) | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
WO2001015676A2 (en) * | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
CO5200852A1 (es) * | 1999-09-14 | 2002-09-27 | Lilly Co Eli | Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides |
US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
WO2002072146A2 (en) * | 2001-03-12 | 2002-09-19 | Novartis Ag | Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
AU2002255732B2 (en) * | 2001-03-14 | 2006-03-09 | Eli Lilly And Company | Fluorinated trienes and their use as RXR modulators |
WO2003007950A1 (en) * | 2001-07-20 | 2003-01-30 | Eli Lilly And Company | (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
JP5249484B2 (ja) * | 2001-12-11 | 2013-07-31 | 第一三共株式会社 | 医薬組成物 |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
US7105566B2 (en) * | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
US6759547B1 (en) | 2003-01-14 | 2004-07-06 | Allergan, Inc. | 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity |
US7019034B2 (en) | 2003-01-28 | 2006-03-28 | Allergan, Inc. | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals |
US6759546B1 (en) | 2003-02-04 | 2004-07-06 | Allergan, Inc. | 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity |
US6884820B2 (en) | 2003-04-03 | 2005-04-26 | Allergan, Inc. | 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity |
US6734193B1 (en) | 2003-06-03 | 2004-05-11 | Allergan, Inc. | (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity |
US6887896B1 (en) | 2003-10-29 | 2005-05-03 | Allergan, Inc. | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity |
ES2433466T3 (es) | 2004-02-27 | 2013-12-11 | Amgen, Inc | Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos |
EP1621191A1 (en) * | 2004-07-29 | 2006-02-01 | Werner Bollag | Treatment of inflammatory diseases by RXR Antagonists |
US20070021612A1 (en) * | 2004-11-04 | 2007-01-25 | University Of Notre Dame Du Lac | Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof |
US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
JP5199079B2 (ja) | 2005-06-17 | 2013-05-15 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アンドロゲン受容体モジュレーター化合物および方法 |
US20070185055A1 (en) * | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
CA2790318A1 (en) * | 2010-02-19 | 2011-08-25 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acti Ng For And On Behalf Of Arizona State University | Novel bexarotene analogs |
WO2013040227A2 (en) | 2011-09-15 | 2013-03-21 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Therapeutic compounds |
JP5877466B2 (ja) * | 2012-02-29 | 2016-03-08 | 国立大学法人 岡山大学 | テルペノイド由来レチノイド化合物 |
PT3094626T (pt) * | 2014-01-14 | 2020-05-22 | Connexios Life Sciences Pvt Ltd | Compostos de heteroarila bicíclica substituída como antagonistas de rxr |
US10328040B2 (en) | 2014-01-17 | 2019-06-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic methods |
CA2962150C (en) | 2014-10-10 | 2023-07-04 | High Force Research Limited | Fluorescent synthetic retinoids |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
US10231947B2 (en) | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
US10238626B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
US10238655B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
EP3588064B1 (en) * | 2017-02-23 | 2022-09-07 | IHI Corporation | Oh radical detection probe, oh radical measurement device, and oh radical measurement method |
CN112218629A (zh) * | 2018-03-01 | 2021-01-12 | Dj疗法有限责任公司 | 贝沙罗汀衍生物及其在治疗癌症中的用途 |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845089A (en) * | 1972-07-27 | 1974-10-29 | Zoecon Corp | Phenylheptadienoates |
US4105681A (en) * | 1975-08-01 | 1978-08-08 | Hoffmann-La Roche Inc. | 9-phenyl 5,6-dimethyl-nona-2,4,6,8-tetraeonic acid compounds |
US4215215A (en) * | 1975-08-01 | 1980-07-29 | Hoffmann-La Roche Inc. | 9-Phenyl-nonate traene compounds |
LU77254A1 (es) * | 1977-05-04 | 1979-01-18 | ||
US4326055A (en) * | 1977-12-22 | 1982-04-20 | Hoffmann-La Roche Inc. | Stilbene derivatives |
DE3202100A1 (de) * | 1982-01-23 | 1983-08-04 | Basf Ag, 6700 Ludwigshafen | Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen |
CH651034A5 (de) | 1982-05-12 | 1985-08-30 | Hoffmann La Roche | Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe. |
US4534979A (en) | 1982-06-28 | 1985-08-13 | Usv Pharmaceutical Corp. | Polyene compounds useful in the treatment of psoriasis and allergic responses |
US4539134A (en) * | 1982-12-02 | 1985-09-03 | Halliburton Company | Methods and cleaning compositions for removing organic materials from metallic surfaces |
US4539154A (en) | 1983-06-15 | 1985-09-03 | Hoffmann-La Roche Inc. | Polyene compounds |
US4648996A (en) * | 1984-07-27 | 1987-03-10 | Hoffmann-La Roche Inc. | Phenyl substituted-2,4,6,8-nonatetraenoic acid |
CH667868A5 (fr) | 1984-09-05 | 1988-11-15 | Oreal | Derives du benzonorbornene, leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant. |
DE3434944A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | L-substituierte tetralinderivate, ihre herstellung und verwendung |
FR2580277B1 (fr) | 1985-04-15 | 1988-06-10 | Oreal | Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant |
LU86022A1 (fr) | 1985-07-25 | 1987-02-04 | Cird | Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique |
JPS62215581A (ja) | 1986-03-18 | 1987-09-22 | Koichi Shiyudo | フラボンカルボン酸誘導体 |
FR2599031B1 (fr) * | 1986-05-23 | 1988-07-22 | Oreal | Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique |
FR2601670B1 (fr) | 1986-07-17 | 1988-10-07 | Cird | Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique |
US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
FR2605626B1 (fr) | 1986-10-27 | 1989-06-02 | Oreal | Nouveaux derives aromatiques bicycliques, leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire |
FR2614618B1 (fr) | 1987-04-30 | 1989-07-07 | Cird | Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire |
US4977276A (en) * | 1987-05-11 | 1990-12-11 | The Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Acting For And On Behalf Of Oklahoma State Univ. | Heteroarotinoids as anticancer agents |
LU87040A1 (fr) | 1987-11-04 | 1989-06-14 | Oreal | Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant |
US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
DE4036779A1 (de) | 1990-11-17 | 1992-05-21 | Basf Ag | Verwendung von arylpolyencarbonsaeuren und ihren derivaten als lichtschutzmittel in kosmetischen zubereitungen |
US5668175A (en) | 1991-08-23 | 1997-09-16 | The Salk Institute For Biological Studies | Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids |
EP1120113A3 (en) | 1991-08-23 | 2003-05-07 | The Salk Institute For Biological Studies | Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormone |
DE10199033I2 (de) * | 1992-04-22 | 2003-01-09 | Ligand Parmaceuticals Inc | Retinoid-x Rezeptor selektive Verbindungen |
CA2093577C (en) | 1992-05-07 | 2006-01-03 | Michael Klaus | Alkyl or alkoxy substituted s-heterocyclic retinoids |
US5552271A (en) | 1992-06-16 | 1996-09-03 | La Jolla Cancer Research Foundation | RXR homodimer formation |
NZ248794A (en) | 1992-09-29 | 1995-01-27 | Adir | 3-carboxy-(and phosphonoxy-)alkatriene-substituted chromene derivatives and medicaments |
JPH08506323A (ja) | 1992-11-25 | 1996-07-09 | ラ ホヤ キャンサー リサーチ ファウンデーション | Rxrホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用 |
US5466861A (en) * | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
WO1994015901A1 (en) * | 1993-01-11 | 1994-07-21 | Ligand Pharmaceuticals Inc. | Compounds having selectivity for retinoid x receptors |
ES2129115T3 (es) * | 1993-01-11 | 1999-06-01 | Ligand Pharm Inc | Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x. |
AU6225894A (en) * | 1993-01-11 | 1994-08-15 | Ligand Pharmaceuticals, Inc. | Compounds having selectivity for retinoid x receptors |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5399586A (en) | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
CA2129773C (en) * | 1993-09-02 | 2007-05-01 | Michael Klaus | Aromatic carboxylic acid derivatives |
WO1995015901A1 (en) * | 1993-12-08 | 1995-06-15 | Beloit Technologies, Inc. | Method and apparatus for effecting a set change in a paper winder |
FR2719042B1 (fr) * | 1994-04-25 | 1996-05-15 | Rhone Poulenc Chimie | Procédé de préparation d'un acide alpha-(hydroxyphénoxy)- alcanecarboxylique optiquement actif. |
FR2719041B1 (fr) * | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
FR2723315B1 (fr) | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
CA2196197C (en) | 1994-08-10 | 2007-04-17 | Michael Klaus | Retinoic acid x-receptor ligands |
US5977125A (en) | 1994-10-31 | 1999-11-02 | Eisai Co., Ltd. | Mono-or polyenic carboxylic acid derivatives |
IL116259A (en) | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
US5968908A (en) | 1994-12-19 | 1999-10-19 | American Cyanamid Company | Restricted 9-cis retinoids |
CZ212097A3 (en) | 1995-01-20 | 1997-11-12 | Novo Nordisk As | Use of 3,4-diphenylchromans for preparing a medicament intended for treating or prophylaxis of cerebral degenerative diseases |
FR2729664A1 (fr) * | 1995-01-20 | 1996-07-26 | Cird Galderma | Composes bicycliques-aromatiques a forte activite biologique compositions pharmaceutiques et cosmetiques les contenant et utilisations |
EP1077919A1 (en) | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | New compounds, their preparation and use |
-
1996
- 1996-09-17 ES ES96935837T patent/ES2190479T3/es not_active Expired - Lifetime
- 1996-09-17 BR BR9610875A patent/BR9610875A/pt not_active Application Discontinuation
- 1996-09-17 JP JP51427597A patent/JP2002515025A/ja not_active Ceased
- 1996-09-17 AU AU73624/96A patent/AU726450B2/en not_active Ceased
- 1996-09-17 CA CA002233888A patent/CA2233888A1/en not_active Abandoned
- 1996-09-17 AT AT96935837T patent/ATE236115T1/de not_active IP Right Cessation
- 1996-09-17 PT PT96935837T patent/PT873295E/pt unknown
- 1996-09-17 EP EP96935837A patent/EP0873295B1/en not_active Expired - Lifetime
- 1996-09-17 DE DE69627193T patent/DE69627193T2/de not_active Expired - Fee Related
- 1996-09-17 EP EP03007532A patent/EP1336600A3/en not_active Withdrawn
- 1996-09-17 KR KR1019980702487A patent/KR100625255B1/ko not_active IP Right Cessation
- 1996-09-17 WO PCT/US1996/014876 patent/WO1997012853A1/en not_active Application Discontinuation
- 1996-09-17 DK DK96935837T patent/DK0873295T3/da active
-
1998
- 1998-04-02 NO NO19981501A patent/NO313186B1/no unknown
-
1999
- 1999-09-02 US US09/388,888 patent/US6545049B1/en not_active Expired - Fee Related
-
2003
- 2003-02-05 US US10/360,580 patent/US20040019072A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1336600A2 (en) | 2003-08-20 |
DE69627193T2 (de) | 2004-01-29 |
EP0873295A1 (en) | 1998-10-28 |
ES2190479T3 (es) | 2003-08-01 |
DK0873295T3 (da) | 2003-07-14 |
DE69627193D1 (de) | 2003-05-08 |
PT873295E (pt) | 2003-08-29 |
WO1997012853A1 (en) | 1997-04-10 |
NO981501D0 (no) | 1998-04-02 |
NO981501L (no) | 1998-06-02 |
EP0873295B1 (en) | 2003-04-02 |
CA2233888A1 (en) | 1997-04-10 |
AU7362496A (en) | 1997-04-28 |
KR100625255B1 (ko) | 2008-01-30 |
US20040019072A1 (en) | 2004-01-29 |
KR19990064010A (ko) | 1999-07-26 |
US6545049B1 (en) | 2003-04-08 |
BR9610875A (pt) | 1999-07-13 |
JP2002515025A (ja) | 2002-05-21 |
ATE236115T1 (de) | 2003-04-15 |
EP1336600A3 (en) | 2004-07-07 |
AU726450B2 (en) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO313186B1 (no) | Dimer-selektive RXR modulatorer, farmasöytisk preparat omfattende samme og anvendelse derav for fremstilling avmedikament | |
US6593493B1 (en) | RXR modulators with improved pharmacologic profile | |
US6083977A (en) | Trienoic retinoid compounds and methods | |
US5770378A (en) | Tricyclic retinoids, methods for their production and use | |
US5770382A (en) | Tricyclic retinoids, methods for their production and use | |
NO310408B1 (no) | Nye trienoiske retinoidforbindelser, fremgangsmåter og anvendelse | |
US5998654A (en) | Retinoic acid receptor antagonist compounds and methods | |
US5770383A (en) | Tricyclic retinoids, methods for their production and use | |
AU2002255732B2 (en) | Fluorinated trienes and their use as RXR modulators | |
US6005007A (en) | Retinoids, methods for their production and use | |
EP0800504B1 (en) | Tricyclic retinoids, methods for their production and use | |
AU2002255732A1 (en) | Fluorinated trienes and their use as RXR modulators | |
AU767255B2 (en) | Dimer-selective RXR modulators and methods for their use | |
US20040248913A1 (en) | (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators | |
AU2002319583A1 (en) | (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators | |
KR20060079254A (ko) | 다이머-선택적 rxr 변조물질 및 그의 사용방법 | |
AU2004200443A1 (en) | Dimer-selective RXR modulators and methods for their use | |
WO2000026172A1 (en) | Trienoic retinoid compounds as retinoic acid receptor antagonists | |
WO2000026173A1 (en) | Novel retinoids, methods for their production and use |